Personalized Medicine Manufacturers Technological Advancements, Revenue Diversification, Patent Expansions, Cross-border Expansion, Performance Gap Identification, Organizational Growth Plans, Operational Excellence

Personalized Medicine Companies and Import/Export Data

The global personalized medicine market was valued at approximately USD 572.93 billion in 2024 and is projected to reach around USD 1,264.67 billion by 2034, growing at a compound annual growth rate (CAGR) of 8.24% during the forecast period from 2024 to 2034.

Top Companies in Personalized Medicine Market

• GE Healthcare
• Illumina, Inc.
• ASURAGEN, INC.
• Abbott
• Dako A/S
• Exact Sciences Corporation
• Danaher Corporation (Cepheid, Inc.)
• Decode Genetics, Inc.
• QIAGEN
• Exagen Inc.
• Precision Biologics
• Celera Diagnostics LLC.
• Biogen
• Genelex
• International Business Machines Corporation (IBM)
• Genentech, Inc.
• 23andMe, Inc.

Recent Developments in the Personalized Medicine Market

• In May 2024, OM1 announced three new products, OM1 Orion, OM1 Lyra, and OM1 Polaris, powered by PhenOMTM, an intelligent digital phenotyping platform for personalized medicine and clinical research. OM1 is a leader in delivering real-world evidence (RWE) insights from the laboratory to the hospital, using advanced predictive and AI techniques and in-depth data analysis to support healthcare stakeholders.
• In September 2024, Odense-based Evosep provides researchers and partners with integrated tools that enable precision medicine and agile processes through a new partnership with US giant Thermo Fisher Scientific.
• In February 2023, Roche announced the expansion of its partnership with Janssen Biotech. (Janssen) to create a companion evaluator for healthcare to advance research and innovation of personalized medicine.

Consignee and Shipper Details for Personalized Medicine and Medical Accessories in the U.S. (2023 - 24)